The FDA expanded Anktiva plus BCG to papillary-only bladder cancer that no longer responds to BCG. Here is who qualifies, what the data show, and what remains uncertain.
FDA Expands Anktiva Approval to Papillary-Only Bladder Cancer That Resists BCG, Giving Patients a Nonsurgical Option
by | Oct 15, 2026 | Uncategorized | 0 comments
Recent Comments